Know Cancer

forgot password

Multi-institutional Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer

Phase 1/Phase 2
Open (Enrolling)
Severe Combined Immunodeficiency

Thank you

Trial Information

Multi-institutional Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer

Severe combined immunodeficiencies (SCID) are a heterogeneous group of inherited disorders
characterized by a profound reduction or absence of T lymphocyte function. They arise from a
variety of molecular defects which affect lymphocyte development and function. The most
common form of SCID is an X-linked form (SCID-X1) which accounts for 40-50% of all cases.
SCID-X1 is caused by defects in the common cytokine receptor chain, which was originally
identified as a component of the high affinity interleukin-2 receptor (IL-2RG), but is now
known to be an essential component of the IL-4, -7, -9 -15, and -21 cytokine receptor
complexes. Classic SCID-X1 has an extremely poor prognosis without treatment. Death usually
occurs in the first year of life from infectious complications unless definitive treatment
can be administered. Until the recent advent of somatic gene therapy, hematopoietic stem
cell transplantation (HSCT) offered the only curative option for patients with any form of
SCID. If a genotypically matched sibling donor is available, HSCT is a highly successful
procedure. However a genotypically matched family donor is only available for approximately
30% of patients. For the remaining individuals, alternative donor transplants, principally
from matched unrelated or haploidentical parental donors have been performed. These
approaches are still problematic with toxicity from ablative therapy, graft-versus-host
disease and incomplete lymphoid reconstitution. Recent gene transfer trials have documented
the efficacy of gene transfer in this disease, albeit with toxicity related to insertional
mutagenesis. A new generation of self-inactivating (SIN) vectors has been developed which
lack all enhancer-promoter elements of the LTR U3 region and are also devoid of all
gammaretroviral coding regions. A SIN vector expressing the IL-2RG gene,
pSRS11.EFS.IL2RG.pre* has been developed and has shown a reduction in mutagenic potential
compared to LTR configuration in non-clinical studies. The current study is a phase I/II
trial of somatic gene therapy for patients with SCID-X1.

Inclusion Criteria:

1. Diagnosis of SCID-X1 based on immunophenotype (<200 CD3+ autologous T cells, and
confirmed by DNA sequencing)


2. Lack an HLA identical (A, B, C, DR, DQ) related donor

AND either one of the following:

1. Patients in good clinical condition who do not have a readily available HLA identical
(A,B,C,DR,DQ) unrelated donor (readily available defined as: a donor confirmed within 6
weeks of searching, with ability to transplant within 3 months of diagnosis).

2. Patients with an active, therapy-resistant infection or other medical conditions that
significantly increase the risk of allogeneic transplant. Examples of "therapy-resistant
infections that significantly increase the risk of allogeneic transplant" include but are
not limited to:

1. interstitial pneumonia due to adenovirus or parainfluenzae virus.

2. protracted diarrhea requiring total parenteral nutrition.

3. disseminated BCG infection.

4. virus-induced lymphoproliferative disease.

5. any active opportunistic infection (eg, due to Pneumocystis jiroveci,
cytomegalovirus,cryptosporidium) that does not improve on medical management.

6. active and progressive pulmonary disease requiring mechanic ventilation. Inclusion of
patients with disease-related organ dysfunction is justified by the known poor
outcome with standard treatment and the potential life-saving nature of the treatment
proposed. Patients who are on high-dose steroids or other immunosuppressive agents
will also be considered eligible, because use of these drugs is common in patients
with SCID and maternal T cell engraftment or who present with severe interstitial
lung disease. Use of immunosuppressive drugs does not affect efficacy of
hematopoietic cell transplantation, and therefore should not affect efficacy of gene

Exclusion Criteria:

1. No available molecular diagnosis confirming SCID-X1.

2. Patients who have an available HLA-identical related donor.

3. Diagnosis of active malignant disease other than EBV-associated lymphoproliferative

4. Patients with evidence of infection with HIV-1

5. Previous gene transfer

6. Major (life-threatening) congenital anomalies. Examples of "major (life-threatening)
congenital anomalies" include, but are not limited to: unrepaired cyanotic heart
disease, hypoplastic lungs, anencephaly or other major CNS malformations, other
severe non-repairable malformations of the gastrointestinal or genitourinary tracts
that significantly impair organ function.

7. Other conditions which in the opinion of the P.I. or co-investigators,
contra-indicate collection and/or infusion of transduced cells or indicate patient's
inability to follow the protocol. These may include for example clinical
ineligibility to receive anesthesia, severe deterioration of clinical condition of
the patient after collection of bone marrow but before infusion of transduced cells,
or documented refusal or inability of the family to return for scheduled visits.
There may be other unforeseen rare circumstances that would result in exclusion of
the patient, such as sudden loss of legal guardianship.

Although the presentation of the disease may be variable in type, the severity of the
immunodeficiency is uniform. The gene transfer protocol will be instituted in the place of
haploidentical transplant for those patients who do not have a matched family donor or in
whom an unrelated donor transplant is not indicated for the reasons specified above.
Apart from the gene transfer protocol, the patients will not undergo additional procedures
that would not form part of an equivalent haploidentical transplantation regimen, and will
not receive conditioning chemotherapy.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

CD3 cell count post transfusion

Outcome Description:

Immunological reconstitution defined as absolute CD3 cells of >300/μl and PHA stimulation index >15 at 6 months post infusion

Outcome Time Frame:

6 Months Post Gene Transfer

Safety Issue:


Principal Investigator

Luigi Notarangelo, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Hospital Boston


United States: Food and Drug Administration

Study ID:




Start Date:

April 2010

Completion Date:

April 2030

Related Keywords:

  • Severe Combined Immunodeficiency
  • Severe combined immunodeficiency
  • SCID
  • SCID-X1
  • Immunologic Deficiency Syndromes
  • Severe Combined Immunodeficiency
  • X-Linked Combined Immunodeficiency Diseases



Children's Hospital Boston Boston, Massachusetts  02115
Cincinnati Children's Medical Center Cincinnati, Ohio  45267
Mattel Children's Hospital - UCLA Los Angeles, California  90095